Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.
The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.
Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding.
Mainstream AML treatments have remained unchanged for over 30 years, with the current treatment being chemotherapy, and the majority of people’s cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.
In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.
In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease – the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.
The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects.
“We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans.”
Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute
SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth.
“Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”
Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and University of Cambridge
“When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer.”
Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases
Learn more: From eye drops to potential leukaemia treatment
The Latest on: Acute myeloid leukaemia
via Google News
The Latest on: Acute myeloid leukaemia
- Leukemia researcher Dr. Jerry Radich receives Kurt Enslein Endowed Chairon August 16, 2019 at 2:38 pm
Radich studies genes and other molecules that signal treatment response, progression and relapse in leukemia patients. He specializes in developing methods to improve the detection and treatment of ...
- 2 Farmington men get to know recipients of bone marrow donationson August 15, 2019 at 9:05 pm
“You want to be that one to be able to do it. I called back and they gave little information, just that it was a 35-year-old female with acute myeloid leukemia. I talked it over with my wife, Kelly, ...
- Leukemia in PCI; Nanotube Conduction Bypass; TAVR for Developing Countrieson August 15, 2019 at 2:37 pm
Leukemia patients faced 41% higher odds of in-hospital mortality and bleeding around percutaneous coronary intervention than did other patients. Acute myeloid leukemia specifically was associated with ...
- A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugson August 14, 2019 at 10:38 am
Mitochondria play a central and multifunctional role in the progression of tumorigenesis. Although many recent studies have demonstrated correlations between mitochondrial function and genetic makeup ...
- Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemiaon August 13, 2019 at 2:20 am
Genomic alterations in cancer are heterogeneous and complex but mainly thought to disturb protein function or gene expression 1. The extent to which such mutations are transcribed into RNA is largely ...
- Mother who dismissed her headaches and fatigue as pregnancy symptoms is diagnosed with LEUKAEMIA and has to delay treatment to have her babyon August 11, 2019 at 10:08 pm
Acute myeloid leukaemia (AML) is a type of blood cancer that starts in young white blood cells in the bone marrow. AML affects around one in 200 men and one in 255 women in the UK at some point in ...
- Biotech Brief: Acute Myeloid Leukemia Market to Reach USD 1.5 Billion Dollars by 2024on August 11, 2019 at 7:46 am
PALM BEACH, Florida: Acute myeloid leukemia (AML) is a cancer that is rarely seen before age 45 with the average age of onset around 65. It is the most common of the four major types of leukemia.
- Mum went to doctors feeling a 'bit rundown' and was told she had leukaemiaon August 10, 2019 at 9:30 pm
Blood tests showed she had acute lymphoblastic leukaemia ... life-threatening condition called Chronic myeloid leukaemia (CML). She underwent further intensive treatment which included additional stem ...
- Leukemia almost ended her life, but Angela fought back and won | Children’s Miracle Networkon August 7, 2019 at 11:27 pm
This time, her bloodwork confirmed the worst. Angela had Acute Myeloid Leukemia, or AML. "I remember sitting with my parents in the waiting room and we cried for about four hours," Angela recalled. "I ...
- Tributes as Norfolk mum-of-four loses four-year battle with leukaemiaon August 6, 2019 at 7:55 am
Heather Bellamy, from Downham Market, who had been fighting acute myeloid leukaemia for four years, died on Saturday, August 3. Friends and family had been desperately trying to raise £250,000 to send ...
via Bing News